0001493152-22-023376.txt : 20220817 0001493152-22-023376.hdr.sgml : 20220817 20220817201712 ACCESSION NUMBER: 0001493152-22-023376 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220815 FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carter Jennifer L. CENTRAL INDEX KEY: 0001806505 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37648 FILM NUMBER: 221176034 MAIL ADDRESS: STREET 1: C/O DFP SPONSOR LLC STREET 2: 780 THIRD AVENUE, 37TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oncocyte Corp CENTRAL INDEX KEY: 0001642380 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 271041563 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-409-7600 MAIL ADDRESS: STREET 1: 15 CUSHING CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20200213 FORMER COMPANY: FORMER CONFORMED NAME: Oncocyte Corp DATE OF NAME CHANGE: 20200205 FORMER COMPANY: FORMER CONFORMED NAME: OncoCyte Corp DATE OF NAME CHANGE: 20150513 4 1 ownership.xml X0306 4 2022-08-15 0 0001642380 Oncocyte Corp OCX 0001806505 Carter Jennifer L. C/O ONCOCYTE CORPORATION 15 CUSHING IRVINE CA 92618 1 0 0 0 Common Stock, no par value 2022-08-15 4 A 0 10000 0 A 20000 D Common Stock, no par value 2022-08-16 4 P 0 10500 0.95 A 30500 D Option to Purchase Common Stock 0.97 2022-08-15 4 A 0 45000 0 A 2032-08-15 Common Stock 45000 45000 D The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders. /s/ Jennifer Levin Carter 2022-08-17